Latest Breaking News On - Antibody radiation conjugates - Page 6 : comparemela.com

Safety Data Highlighting Low Rates of Adverse Events and Non-Relapse Transplant Related Mortality in Patients Receiving Iomab-B Presented at 2021 SNMMI Virtual Conference

Safety Data Highlighting Low Rates of Adverse Events and Non-Relapse Transplant Related Mortality in Patients Receiving Iomab-B Presented at 2021 SNMMI Virtual Conference
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Neeta pandit paskarHans vitzthumMark bergerCompany phaseLifesci advisorsPatient groupExchange commissionAstellas pharma incActinium pharmaceuticals incSociety of nuclear medicineMemorial sloan kettering cancer centerActinium pharmaceuticalsAcute myeloid leukemiaNuclear medicineMolecular imagingAnnual meeting

Pivotal Phase 3 SIERRA Trial Data Showing 100% Bone Marrow Transplant Engraftment in Patients Treated with Iomab-B presented at the 2021 Virtual SNMMI Conference

Pivotal Phase 3 SIERRA Trial Data Showing 100% Bone Marrow Transplant Engraftment in Patients Treated with Iomab-B presented at the 2021 Virtual SNMMI Conference
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Susan passalaquaHans vitzthumMark bergerCompany phaseLifesci advisorsExchange commissionAstellas pharma incActinium pharmaceuticals incBanner md anderson cancer centerSociety of nuclear medicineMemorial sloan kettering cancer centerActinium pharmaceuticalsNuclear medicineMolecular imagingAnnual meetingChief medical officer

Actinium Announces Several Presentations from the Phase 3 SIERRA Study of Iomab-B at the SNMMI 2021 Virtual Annual Meeting

/PRNewswire/ Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that three abstracts highlighting data and.

United kingdomRoberto fedrigoSusan passalaquaSandesh sethHans vitzthumMark bergerLifesci advisorsExchange commissionAstellas pharma incActinium pharmaceuticals incUniversity of british columbiaBanner md anderson cancer centerSociety of nuclear medicineMemorial sloan kettering cancer centerBc cancer research instituteActinium pharmaceuticals

Actinium Announces Appointment of Mark Kubik, MBA as Chief Business Officer

Actinium Announces Appointment of Mark Kubik, MBA as Chief Business Officer
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesLeeds school of businessSandesh sethHans vitzthumMark kubikOncoimmune merckLifesci advisorsPharmaceuticals velocity sciencesGlenmark pharmaceuticalsAlliance of the yearExchange commissionLicensing executives societyAstellas pharma incUniversity of coloradoActinium pharmaceuticals incMemorial sloan kettering cancer center

Actinium and Astellas Announce Research Collaboration Focused on Novel Actinium-225 Based Targeted Radiotherapies

Share this article NEW YORK, Jan. 13, 2021 /PRNewswire/ Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ( Actinium ) today announced the research collaboration with Astellas Pharma Inc. (TSE:4503) ( Astellas ) to develop novel targeted radiotherapies using its Antibody Warhead Enabling (AWE) technology platform. Under this agreement, Actinium will utilize its AWE Platform technology to develop and characterize selected Astellas targeting agents labeled with the potent alpha-emitting radioisotope Actinium-225 (Ac-225). This collaboration is a component of Astellas internal initiative to develop theranostics as part of its Rx+ ® business (For more information, please visit https://www.astellas.com/en/news/16356). We are excited to execute on this research collaboration with Astellas, a global leader at the forefront of healthcare innovation, stated Dr. Dale Ludwig, Chief Scientific and Technology Officer of Actinium. Targeted radiotherapy has a highly differentiated

United statesDale ludwigSandesh sethHans vitzthumClayton robertsonLifesci advisorsOur antibody warhead enabling platform technologyTechnology platformPlatform technologyExchange commissionAstellas pharma incActinium pharmaceuticals incBusiness developmentActinium pharmaceuticalsAstellas pharmaAntibody warhead enabling